Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of carpal tunnel, published as a randomized controlled trial.

Who Took Part

According to the abstract, 18, men were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.

The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The first six months was a period of baseline observation.

Lean body mass and adipose mass were measured every six months.

What Was Measured

The subject headings attached to it are Adipose Tissue, Body Composition, Body Mass Index, Carpal Tunnel Syndrome, Growth Hormone, Gynecomastia and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18, men in people with carpal tunnel.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1993 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Carpal tunnel research.